Given that FOXL2 expression has been reported in some breast (21) and cervical (22) cancers, we don’t exclude that, in addition to being a marker and target in GCT, FOXL2 could be a potential target in those malignancies where its expression is elevated. Here, FOXL2 is linked to cancer.